Abstract
Huntington's disease (HD) is caused by an expanded CAG trinucleotide repeat encoding a tract of consecutive glutamines near the amino terminus of huntingtin, a large protein of unknown function. It has been proposed that the expanded polyglutamine stretch confers a new property on huntingtin and thereby causes cell and region-specific neurodegeneration. Genotype-phenotype correlations predict that this novel property appears above a threshold length (∼38 glutamines), becomes progressively more evident with increasing polyglutamine length, is completely dominant over normal huntingtin and is not appreciably worsened by a double genetic dose in HD homozygotes. Recently, an amino terminal fragment of mutant huntingtin has been found to form self-initiated fibrillar aggregates in vitro. We have tested the capacity for aggregation to assess whether this property matches the criteria expected for a fundamental role in HD pathogenesis. We find that that in vitro aggregation displays a threshold and progressivity for polyglutamine length remarkably similar to the HD disease process. Moreover, the mutant huntingtin amino terminus is capable of recruiting into aggregates normal glutamine tract proteins, such as the amino terminal segments of both normal huntingtin and of TATA-binding protein (TBP). Our examination of in vivo aggregates from HD post-mortem brains indicates that they contain an amino terminal segment of huntingtin of between 179 and 595 residues. They also contain non-huntingtin protein, as evidenced by immunostaining for TBP. Interestingly, like the in vitro aggregates, aggregates from HD brain display Congo red staining with green birefringence characteristic of amyloid. Our data support the view that the expanded polyglutamine segment confers on huntingtin a new property that plays a determining role in HD pathogenesis and could be a target for treatment. Moreover, the new property might have its toxic consequences by interaction with one or more normal polyglutamine-containing proteins essential for the survival of target neurons.
Similar content being viewed by others
LITERATURE CITED
Gusella, J.F., Persichetti, F., and MacDonald, M.E. (1997). The genetic defect causing Huntington's disease: repeated in other contexts? Mol. Med. 3:238–246.
Holmberg, M., Duyckaerts, C., Durr, A., Cancel, G., Gourfinkel-An, I., Damier, P., Faucheux, B., Trottier, Y., Hirsch, E.C., Agid, Y., and Brice, A. (1998). Spinocerebellar ataxia type 7 (SCA7): a neurodegenerative disorder with neuronal intranuclear inclusions. Hum. Mol. Genet. 7:913–918.
Ross, C.A. (1997). Intranuclear neuronal inclusions: a common pathogenic mechanism for glutamine-repeat neurodegenerative diseases? Neuron 19:1147–1150.
Huntington's Disease Collaborative Research Group (1993). A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72:971–983.
Duyao, M.P., Auerbach, A.B., Ryan, A., Persichetti, F., Barnes, G.T., McNeil, S.M., Ge, P., Vonsattel, J.P., Gusella, J.F., Joyner, A.L., and MacDonald, ME. (1995). Inactivation of the mouse Huntington's disease gene homolog Hdh. Science 269:407–410.
Zeitlin, S., Liu, J.P., Chapman, D.L., Papaioannou, V.E., and Efstratiadis, A. (1995). Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue. Nat. Genet. 11:155–163.
Nasir, J., Floresco, S.B., JR, O.K., Diewert, V.M., Richman, J.M., Zeisler, J., Borowski, A., Marth, J.D., Phillips, A.G., and Hayden, M.R. (1995). Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell 81:811–823.
White, J.K., Auerbach, W., Duyao, M.P., Vonsattel, J.P., Gusella, J.F., Joyner, A.L., and MacDonald, M.E. (1997). Huntingtin is required for neurogenesis and is not impaired by the Huntington's disease CAG expansion. Nat. Genet. 17:404–410.
Vonsattel, J.P., and DiFiglia, M. (1998). Huntington disease. J. Neuropathol. Exp. Neurol. 57:369–384.
McNeil, S.M., Novelletto, A., Srinidhi, J., Barnes, G., Kornbluth, I., Altherr, M.R., Wasmuth, J.J., Gusella, J.F., MacDonald, M.E., and Myers, R.H. (1997). Reduced penetrance of the Huntington's disease mutation. Hum. Mol. Genet. 6:775–779.
Rubinsztein, D.C., Leggo, J., Coles, R., Almqvist, E., Biancalana, V., Cassiman, J.J., Chotai, K., Connarty, M., Crauford, D., Curtis, A., Curtis, D., Davidson, M.J., Differ, A.M., Dode, C., Dodge, A., Frontali, M., Ranen, N.G., Stine, O.C., Sherr, M., Abbott, M.H., Franz, M.L., Graham, C.A., Harper, P.S., Hedreen, J.C., Jackson, A., Kaplan, J.C., Losekoot, M., MacMillan, J.C., Morrison, P., Trottier, Y., Novelletto, A., Simpson, S.A., Theilmann, J., Whittaker, J.L., Folstein, S.E., Ross, C.A., and Hayden, M.R. (1996). Phenotypic characterization of individuals with 30–40 CAG repeats in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36–39 repeats. Am. J. Hum. Genet. 59:16–22.
MacDonald, M.E., Barnes, G., Srinidhi, J., Duyao, M.P., Ambrose, C.M., Myers, R.H., Gray, J., Conneally, P.M., Young, A., Penney, J., Shoulson, I., Hollingsworth, Z., Koroshetz, W., Bird, E., Vonsattel, J.P., Bonilla, E., Moskowitz, C., Penchaszadeh, G., Brzustowicz, L., Alvir, J., Bickhem Conde, J., Cha, J-H., Dure, L., Gomez, F., Ramos-Arroyo, M., Sanchez-Ramos, J., Snodgrass, S.R., de Young, M., Waxler, N.S., MacFarlane, H., Anderson, M.A., Jenkins, B., and Gusella, J.F. (1993). Gametic but not somatic instability of CAG repeat length in Huntington's disease. J. Med. Genet. 30:982–986.
Cummings, C.J., Mancini, M.A., Antalffy, B., DeFranco, D.B., Orr, H.T., and Zoghbi, H.Y. (1998). Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1. Nat. Genet. 19:148–154.
Davies, S.W., Turmaine, M., Cozens, B.A., DiFiglia, M., Sharp, A.H., Ross, C.A., Scherzinger, E., Wanker, E.E., Mangiarini, L., and Bates, G.P. (1997). Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90:537–548.
DiFiglia, M., Sapp, E., Chase, K.O., Davies, S.W., Bates, G.P., Vonsattel, J.P., and Aronin, N. (1997). Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277:1990–1993.
Merry, D.E., Kobayashi, Y., Bailey, C.K., Taye, A.A., and Fischbeck, K.H. (1998). Cleavage, aggregation and toxicity of the expanded androgen receptor in spinal and bulbar muscular atrophy. Hum. Mol. Genet. 7:693–701.
Ordway, J.M., Tallaksen-Greene, S., Gutekunst, C.A., Bernstein, E.M., Cearley, J.A., Wiener, H.W., Dure, L.S.T., Lindsey, R., Hersch, S.M., Jope, R.S., Albin, R.L., and Detloff, P.J. (1997). Ectopically expressed CAG repeats cause intranuclear inclusions and a progressive late onset neurological phenotype in the mouse. Cell 91:753–763.
Paulson, H.L., Perez, M.K., Trottier, Y., Trojanowski, J.Q., Subramony, S.H., Das, S.S., Vig, P., Mandel, J.L., Fischbeck, K.H., and Pittman, R.N. (1997). Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3. Neuron 19:333–344.
Perutz, M.F., Johnson, T., Suzuki, M., and Finch, J.T. (1994). Glutamine repeats as polar zippers: their possible role in inherited neurodegenerative diseases. Proc. Natl. Acad. Sci. U.S.A. 91:5355–5358.
Green, H. (1993). Human genetic diseases due to codon reiteration: relationship to an evolutionary mechanism. Cell 74:955–956.
Cooper, A.J.L., Sheu, K.R., Burke, J.R., Onodera, O., Strittmatter, W.J., Roses, A.D., and Blass, J.P. (1997). Transglutaminase-catalyzed inactivation of glyceraldehyde 3-phosphate dehydrogenase and alpha-ketoglutarate dehydrogenase complex by polyglutamine domains of pathological length. Proc. Natl. Acad. Sci. U.S.A. 94:12604–12609.
Cooper, A.J., Sheu, K.F., Burke, J.R., Onodera, O., Strittmatter, W.J., Roses, A.D. and Blass, J.P. (1997). Polyglutamine domains are substrates of tissue transglutaminase: does transglutaminase play a role in expanded CAG/poly-Q neurodegenerative diseases? J. Neurochem. 69:431–434.
Gentile, V., Sepe, C., Calvani, M., Melone, M.A., Cotrufo, R., Cooper, A.J., Blass, J.P., and Peluso, G. (1998). Tissue transglutaminase-catalyzed formation of high-molecular-weight aggregates in vitro is favored with long polyglutamine domains: a possible mechanism contributing to CAG-triplet diseases. Arch. Biochem. Biophys. 352:314–321.
Kahlem, P., Terre, C., Green, H., and Djian, P. (1996). Peptides containing glutamine repeats as substrates for transglutaminase-catalyzed cross-linking: relevance to diseases of the nervous system. Proc. Natl. Acad. Sci. U.S.A. 93:14580–14585.
Kahlem, P., Green, H., and Djian, P. (1998). Transglutaminase action imitates Huntington's disease: selective polymerization of Huntingtin containing expanded polyglutamine. Mol. Cell 1:595–601.
Scherzinger, E., Lurz, R., Turmaine, M., Mangiarini, L., Hollenbach, B., Hasenbank, R., Bates, G.P., Davies, S.W., Lehrach, H., and Wanker, E.E. (1997). Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell 90:549–558.
Huang, C.C., and Herr, W. (1996). Differential control of transcription by homologous homeodomain coregulators. Mol. Cell. Biol. 16:2967–2976.
Mittal, V., and Hernandez, N. (1997). Role for the amino-terminal region of human TBP in U6 snRNA transcription. Science 275:1136–1140.
Schende, P.F. (1992). Protein expression. In: Current Protocols in Molecular Biology, Eds: Ausubel, F.M., Brent, R., Kingston, R.E., Moore, D.D., Seidman, J.G., Smith, J.A., and Struhl, K. (New York: John Wiley and Sons).
Lobo, S., Ruppert, S.M., McCulloch, V., Meyer, M., Bautista, C., Falkowski, M., Stunnenberg, H.G., and Hernandez, N. (1996). Monoclonal antibodiesdirected against the amino-terminal domain of human TBP cross-react with TBP from other species. Hybridoma 15:55–68.
Aronin, N., Chase, K., Sagar, S.M., Sharp, F.R., and DiFiglia, M. (1991). N-methyl-D-aspartate receptor activation in the neostriatum increases c-fos and fos-related antigens selectively in medium-sized neurons. Neuroscience 44:409–420.
Turnell, W.G., and Finch, J.T. (1992). Binding of the dye congo red to the amyloid protein pig insulin reveals a novel homology amongst amyloid-forming peptide sequences. J. Mol. Biol. 227:1205–1223.
Gusella, J.F., McNeil, S., Persichetti, F., Srinidhi, J., Novelletto, A., Bird, E., Faber, P., Vonsattel, J.P., Myers, R.H., and MacDonald, M.E. (1996). Huntington's Disease. Cold Spring Harbor Symposia on Quantitative Biology LXI:615–625.
Myers, R.H., Leavitt, J., Farrer, L.A., Jagadeesh, J., McFarlane, H., Mastromauro, C.A., Mark, R.J., and Gusella, J.F. (1989). Homozygote for Huntington disease. Am. J. Hum. Genet. 45:615–618.
Wexler, N.S., Young, A.B., Tanzi, R.E., Travers, H., Starosta-Rubinstein, S., Penney, J.B., Snodgrass, S.R., Shoulson, I., Gomez, F., Ramos Arroyo, M.A., and et al. (1987). Homozygotes for Huntington's disease. Nature 326:194–197.
Trottier, Y., Lutz, Y., Stevanin, G., Imbert, G., Devys, D., Cancel, G., Saudou, F., Weber, C., David, G., Tora, L., Agid, Y., Hirsch, E.C., and Mandel, J-L. (1995). Polyglutamine expansion as a pathological epitope in Huntington's disease and four dominant cerebellar ataxias. Nature 378:403–406.
Persichetti, F., Ambrose, C.M., Ge, P., McNeil, S.M., Srinidhi, J., Anderson, M.A., Jenkins, B., Barnes, G.T., Duyao, M.P., Kanaley, L., Waxler, N.S., Myers, R.H., Bird, E.D., Vonsattel, J.P., MacDonald, M.E., and Gusella, J.F. (1995). Normal and expanded Huntington's disease gene alleles produce distinguishable proteins due to translation across the CAG repeat. Mol. Med. 1:374–383.
Persichetti, F., Carlee, L., Faber, P.W., McNeil, S.M., Ambrose, C.M., Srinidhi, J., Anderson, M., Barnes, G.T., Gusella, J.F., and MacDonald, M.E. (1996). Differential expression of normal and mutant Huntington's disease gene alleles. Neurobiol. Dis. 3:183–190.
Klement, I.A., Skinner, P.J., Kaytor, M.D., Yi, H., Hersch, S.M., Clark, H.B., Zoghbi, H.Y., and Orr, H.T. (1998). Ataxin-1 nuclear localization and aggregation: role in polyglutamine-induced disease in SCA1 transgenic mice. Cell 95:41–53.
Wellington, C.L., Ellerby, L.M., Hackam, A.S., Margolis, R.L., Trifiro, M.A., Singaraja, R., McCutcheon, K., Salvesen, G.S., Propp, S.S., Bromm, M., Rowland, K.J., Zhang, T., Rasper, D., Roy, S., Thornberry, N., Pinsky, L., Kakizuka, A., Ross, C.A., Nicholson, D.W., Bredesen, D.E., and Hayden, M.R. (1998). Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract. J. Biol. Chem. 273:9158–9167.
Cooper, J.K., Schilling, G., Peters, M.F., Herring, W.J., Sharp, A.H., Kaminsky, Z., Masone, J., Khan, F.A., Delanoy, M., Borchelt, D.R., Dawson, V.L., Dawson, T.M., and Ross, C.A. (1998). Truncated N-terminal fragments of huntingtin with expanded glutamine repeats form nuclear and cytoplasmic aggregates in cell culture. Hum. Mol. Genet. 7:783–790.
Hackam, A.S., Singaraja, R., Wellington, C.L., Metzler, M., McCutcheon, K., Zhang, T., Kalchman, M., and Hayden, M.R. (1998). The influence of huntingtin protein size on nuclear localization and cellular toxicity. J. Cell Biol. 141:1097–1105.
Li, S.H., and Li, X.J. (1998). Aggregation of N-terminal huntingtin is dependent on the length of its glutamine repeats. Hum. Mol. Genet. 7:777–782.
Liu, Y.F. (1998). Expression of polyglutamine-expanded Huntingtin activates the SEK1-JNK pathway and induces apoptosis in a hippocampal neuronal cell line. J. Biol. Chem. 273:28873–28877.
Lunkes, A., and Mandel, J.L. (1998). A cellular model that recapitulates major pathogenic steps of Huntington's disease. Hum. Mol. Genet. 7:1355–1361.
Martindale, D., Hackam, A., Wieczorek, A., Ellerby, L., Wellington, C., McCutcheon, K., Singaraja, R., Kazemi-Esfarjani, P., Devon, R., Kim, S.U., Bredesen, D.E., Tufaro, F., and Hayden, M.R. (1998). Length of huntingtin and its polyglutamine tract influences localization and frequency of intracellular aggregates. Nat. Genet. 18:150–154.
Saudou, F., Finkbeiner, S., Devys, D., and Greenberg, M.E. (1998). Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 95:55–66.
Dragatsis, I., Efstratiadis, A., and Zeitlin, A. (1998). Mouse mutant embryos lacking huntingtin are rescued from lethality by wild-type extraembryonic tissues. Development 125:1529–1539.
Gusella, J.F., and MacDonald, M.E. (1998). Huntingtin: A single bait hooks many species. Curr. Opin. Neurobiol. 8:425–430.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Huang, C.C., Faber, P.W., Persichetti, F. et al. Amyloid Formation by Mutant Huntingtin: Threshold, Progressivity and Recruitment of Normal Polyglutamine Proteins. Somat Cell Mol Genet 24, 217–233 (1998). https://doi.org/10.1023/B:SCAM.0000007124.19463.e5
Issue Date:
DOI: https://doi.org/10.1023/B:SCAM.0000007124.19463.e5